Current treatments for Parkinson’s disease (PD) are based on dopamine replacement therapy, including L-3, 4-dihydroxyphenylalnine (levodopa, L-DOPA), dopamine agonists (DA), monoamine oxidase B inhibitors (MAOB-I), and cathechol-O-methyltransferase inhibitors (COMT-I). Istradefylline is a selective antagonist of the adenosine A2A receptor, and has been approved for use in PD with regard to anti-parkinsonian effects in patients with wearing-off symptoms  . A recent phase III trial demonstrated that the oral administration of istradefylline (20 mg) reduced off time in patients, while 40 mg of istradefylline improved part III of the Unified Parkinson’s disease Rating scale (UPDRS) during on-phase  . However, the clinical results were inconsistent. While istradefylline demonstrated prominent effects in a number of patients; others experienced little or no benefit. Therefore, to elucidate the epidemiological differences between istradefylline responders and non-responders, a retrospective analysis was performed.
2. Methods and Materials
Patients with PD were recruited according to the following specifications: 1) patients were diagnosed on the basis of the UK PD Brain Bank criteria  ; 2) patients were medicated with levodopa and experienced wearing off; 3) patients featured a rating between 0 and 4 on the modified Hoehn and Yahr (H&Y) scale during the on-phase; and 4) patients wanted to reduce their off-phase disability and received 20 mg/day of istradefylline once in the morning in A.Y.’s outpatient clinic at the Juntendo University Koshigaya hospital between October 2013 and October 2015. Participants were excluded based on the following criteria: 1) patients experienced Parkinsonism due to diseases other than PD; 2) patients were diagnosed with other serious diseases, malignant tumors, or adverse events caused by drugs. All patients provided informed consent prior to the data collection. This study was approved by the Juntendo Koshigaya Hospital Institutional Ethics Committee.
Upon initiation of istradefylline (baseline) treatment and after the 8th week visit, patients were examined according to the UPDRS  , Epworth sleepiness scale (ESS),  on time and off time, and sleeping time, which were recorded in an on/off hourly diary for one week. Responders were evaluated according to the criteria: “very much improved,” “much improved,” and “minimally improved,” while non-responders were defined as “no change” and “worsened” using the Patients Global Impression of Improvement.
2.3. Statistical Analysis
We compared the two groups by using either t-test or χ2-test using SPSS (Version 20.0). Two-sided statistical tests were used and the significance level was set at 0.05.
The epidemiological characteristics of 31 Japanese patients (male 11, female 20)
Table 1. Patient characteristics at baseline and the 8th week.
*p < 0.05, **p < 0.01.
are displayed in Table 1. Istradefylline significantly increased On-time (p < 0.01), and decreased Off-time (p < 0.01), total UPDRS (p < 0.05), and UPDRS part II (p < 0.05) in patients with PD associated motor complications. Twenty one patients were responsive to istradefylline, while 10 patients did not demonstrate any therapeutic benefit. One patient who experienced auditory hallucinations was included in the non-responder group. The dyskinesia severity score (UPDRS) increased from 1 to 2 in several of the responders (n = 2). Other responders experienced slight euphoria (n = 2). Subsequent analysis identified significant differences in the baseline characteristics of responders (n = 21) and non-responders (n = 10) with regard to sex, age, age at onset, age at dyskinesia onset, and ESS (Table 2). No differences were detected in disease duration or daily levodopa dosage. The ESS of non-responders was improved by istradefylline treatment, but was not significant. Regression analysis of changes in On- or Off-time did not indicate any correlations, and logistic regression analysis demonstrated that the odds ratio for non-responders was 1.519 (95% confidence interval 1.021 - 2.261, p = 0.039) in ESS. No correlation was detected between the effects of istradefylline and the therapeutic combination of DA, COMT-I, selegiline, and zonisamide. In the non-responder group, with the exception of one patient with hallucinations, no improvements were detected after istradefylline treatment with 40 mg.
This study demonstrated the therapeutic efficacy of istradefylline with regard to increasing On-time and reducing Off-time, and UPDRS-ADL (part II) score
Table 2. Clinical differences of responders and non-responders to istradefylline.
UPDRS: Unified Parkinson’s disease Rating scale, *p < 0.05, **p < 0.01.
without affecting sleepiness. The majority of anti-parkinsonian drugs produce sleepiness in patients, excluding anti-cholinergics, amantagine, and selegiline; however, istradefylline maintains the level of sleepiness. Significant differences were detected between responders and non-responders in relation to sex, age, age at onset, and ESS. The study found no differences between the groups with regard to disease duration, daily or cumulative levodopa dose, duration of baseline On- or Off-time, or the age at the onset of wearing off. In addition, no differences were detected in the duration of dyskinesia between the two groups; however, the onset of dyskinesia was earlier than that of wearing off in responders. This might relate to the increase in putamen adenosine A2A receptors observed in PD patients with dyskinesia  .
Caffeine is an adenosine A2A antagonist that induces wakefulness via pre adenosine A2A receptors  . In the present study, the level of sleepiness correlated with the effects of istradefylline; therefore, patients who maintain sleep control might be suitable for istradefylline therapy.
Patients with PD demonstrate adenosine A2A receptor up-regulation in lymphocyte membranes compared to healthy subjects  . No differences in A2A receptor parameters were detected in relation to age, age at onset, or disease duration strata. Patients with a greater density of A2A receptors were more likely to experience motor complications  . In the present study, earlier onset of dyskinesia correlated with the effectiveness of istradefylline; however, the duration of dyskinesia was unrelated. Accordingly, the daily levodopa dose, levodopa equivalent dose, and the levodopa cumulative dose were not linked to the effectiveness of the adenosine A2A antagonist istradefylline in this study.
Previous studies did not identify increased responsiveness to istradefylline in female patients with PD. The adenosine A2A receptor antagonist ATL 444 demonstrated reduced sensitivity in male compared to female rats  . However, the mechanisms underlying sex-related differences in adenosine A2A receptor sensitivity were not identified, although ovarian hormones are reported to increase the sensitivity of the D2/A2A receptor system in females  . The efficacy on the reduction of daily Off-time shown in four of the five randomized controlled, double blinded, multicenter trials (Table 3)     . A Japanese phase III trial that included more female subjects than the western trial demonstrated
Table 3. Off-time change from baseline of the randomized multicenter trials of Istradefylline.
a reduction in daily Off-time in the istradefylline group  . In a western Phase III trial, KW-6002-US-018, a reduction in Off-time was −1.3 hours in the placebo group, and it was −1.1 hours in the 20 mg of istradefylline group  , and their baseline characteristics were similar to the present study, excluding those regarding race and sex. Although, other two Western studies including the same ratio of sex, showed the efficacy on the reduction of Off-time   (Table 3).
This study featured several limitations. Primarily, the present study featured a small population; therefore, a larger study will be required to validate these results. Second, this was an open study, and it was not possible to rule out the placebo effect. In addition, the previous Japanese phase III trial revealed a 0.28 h increase in On-time, and a 0.23 h reduction in Off-time in the placebo group, therefore, additional effects need to be explored to elucidate this  . The placebo effects in female subjects are described in one report, which stated that female subjects with both lower dispositional anxiety and cortisol levels showed the largest vasopressin-induced modulation of placebo effects  . However, Shetty et al. analyzed the placebo effects in PD from 22 reports and a DATATOP study and found no correlation with age and gender  . In addition, Goetz et al. reported that gender, age, disease duration, and baseline disability score did not influence the likelihood of improvement in association with placebo treatment  .
In summary, our results cannot deny placebo effects; however, this study suggests that younger or female patients who are not excessively sleepy during the daytime are better candidates for istradefylline therapy.
 Mori, A. and Shindou, T. (2003) Modulation of GABAergic Transmission in the Striatopallidal System by Adenosine A2A Receptors: A Potential Mechanism for the Antiparkinsonian Effects of A2A Antagonists. Neurology, 61, S44-S48.
 Mizuno, Y. and Kondo, T., Japanese Istradefylline Study Group (2013) Adenosine A2A Receptor Antagonist Istradefylline Reduces Daily OFF Time in Parkinson’s Disease. Movement Disorders, 28, 1138-1141.
 Hughes, A.J., Daniel, S.E., Kilford, L. and Lees, A.J. (1992) Accuracy of Clinical Diagnosis of Idiopathic Parkinson’s Disease: A Clinico-Pathological Study of 100 Cases. Journal of Neurology, Neurosurgery & Psychiatry, 55, 181-184.
 Fahn, S. and Elton, R., Members of the UPDRS Development Committee (1987) In: Fahn, S., Marsden, C.D., Calne, D.B. and Goldstein, M., Eds., Recent Developments in Parkinson’s Disease, Vol. 2, Macmillan Healthcare Information, Florham Park, 153-163.
 Tomlinson, C.L., Stowe, R., Patel, S., Rick, C., Gray, R. and Clarke, C.E. (2010) Systematic Review of Levodopa Dose Equivalency Reporting in Parkinson’s Disease. Movement Disorders, 25, 2649-2653.
 Mishina, M., Ishiwata, K., Naganawa, M., Kimura, Y., Kitamura, S., Suzuki, M., Mishina, M., Ishiwata, K., Naganawa, M., Kimura, Y. and Kitamura, S. (2011) Adenosine A2A Receptors Measured with [11C]TMSX PET in the Striata of Parkinson’s Disease Patients. PLoS ONE, 6, e17338.
 Huang, Z.L., Qu, W.M., Eguchi, N., Chen, J.F., Schwarzschild, M.A., Fredholm, B.B., Urade, Y. and Hayaishi, O. (2005) Adenosine A2A, but Not A1, Receptors Mediate the Arousal Effect of Caffeine. Nature Neuroscience, 8, 858-859.
 Casetta, I., Vincenzi, F., Bencivelli, D., Corciulo, C., Gentile, M., Granieri, E., Borea, P.A. and Varani, K. (2014) A2A Adenosine Receptors and Parkinson’s Disease Severity. Acta Neurologica Scandinavica, 129, 276-281.
 Doylea, S.E., Breslina, F.J., Riegerb, J.M., Beaugleholeb, A. and Lyncha, W.J. (2012) Time and Sex-Dependent Effects of an Adenosine A2A/A1 Receptor Antagonist on Motivation to Self-Administer Cocaine in Rats. Pharmacology Biochemistry and Behavior, 102, 257-263.
 LeWitt, P.A., Guttman, M., Tetrud, J.W., Tuite, P.J., Mori, A., Chaikin, P. and Sussman, N.M., 6002-US-005 Study Group (2008) Adenosine A2A Receptor Antagonist Istradefylline (KW-6002) Reduces “off” Time in Parkinson’s Disease: A Double-Blind, Randomized, Multicenter Clinical Trial (6002-US-005). Annals of Neurology, 63, 295-302.
 Hauser, R.A., Shulman, L.M., Trugman, J.M., Roberts, J.W., Mori, A., Ballerini, R. and Sussman, N.M., Istradefylline 6002-US-013 Study Group (2008) Study of Istradefylline in Patients with Parkinson’s Disease on Levodopa with Motor Fluctuations. Movement Disorders, 23, 2177-2185.
 Pourcher, E., Fernandez, H.H., Stacy, M., Mori, A., Ballerini, R. and Chaikin, P. (2012) Istradefylline for Parkinson’s Disease Patients Experiencing Motor Fluctuations: Results of the KW-6002-US-018 Study. Parkinsonism and Related Disorders, 18, 178-184.
 Mizuno, Y., Hasegawa, K., Kondo, T., Kuno, S. and Yamamoto, M., The Japanese Istradefylline Study Group (2010) Clinical Efficacy of Istradefylline (KW-6002) in Parkinson’s Disease: A Randomized, Controlled Study. Movement Disorders, 25, 1437-1443.
 Colloca, L., Pine, D.S., Ernst, M., Miller, F.G. and Grillon, C. (2016) Vasopressin Boosts Placebo Analgesic Effects in Women: A Randomized Trial. Biological Psychiatry, 79, 794-802.